XML 266 R220.htm IDEA: XBRL DOCUMENT
v3.24.0.1

List of principal companies included in the scope of consolidation during 2023 - Summary of Principal Companies and their Country of Incorporation (Details) | 12 Months Ended
--- | ---
Dec. 31, 2023
Hoechst GmbH | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Deutschland GmbH | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
A. Nattermann & Cie. GmbH | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis GmbH | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Belgium | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Ablynx NV | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Flanders BV | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi A/S | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis SA | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Spain, SL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Oy | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis France | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Winthrop Industrie | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Recherche & Développement | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Groupe | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Chimie | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Participations | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventis Pharma S.A. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Biotechnology | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Mature IP | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur NVL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Europe | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
SECIPE SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Merieux SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare International SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare France SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Group SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Polyclonals SAS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis A.E.B.E. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Private Co, Ltd | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.60%
Chinoin Private Co. Ltd | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.60%
Opella Healthcare Hungary Commercial K.F.T | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.60%
Opella Healthcare Hungary K.F.T | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.60%
Carraig Insurance DAC | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Ireland Limited | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Holdings (Ireland) Ltd | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi SRL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Italy SRL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Global Sarl | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Luxembourg Sarl | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Norge AS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi BV | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Foreign Participations BV | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Sp. z.o.o. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Poland sp.z.o.o. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Sp. z.o.o. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Produtos Farmaceuticos Lda | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis, s.r.o. | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Czech s.r.o | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Romania SRL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Romania SRL | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis UK Holdings Limited | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventis Pharma Limited | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Synthelabo UK Ltd | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventis Pharma Holdings Ltd | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare UK Limited | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
AO Sanofi Russia | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare LLC | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi AB | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis (Suisse) SA | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Global Sarl Baar Intellectual Property Branch | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Ilac Sanayi ve Ticaret AS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Asi Ticaret AS | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Tüketici Sağlığı Anonim Şirketi | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Saglik Urunleri Limited Sirketi | Europe |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Therapeutic Products Limited Partnership | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventis Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi US Services Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis U.S. LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Chattem, Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventisub LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Genzyme Corporation | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
VaxServe, Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Bioverativ Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Bioverativ U.S. LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Bioverativ Therapeutics Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Principia Biopharma Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Research Invest LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Bioverativ Holdings LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
RPR US Ltd. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Kadmon Corporation, LLC | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Amunix | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Synthorx, Inc | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Provention Bio | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
QRIB Intermediate Holding | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
QRI | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
TargeGen Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Chattem (GB) Holding | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Translate Bio, Inc. | United States |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis South Africa (Pty) Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Algérie | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Arabia Trading Company Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Argentina SA | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Healthcare Pty Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Australia Pty Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Medley Farmaceutica Ltda | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Brazil Ltda. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Canada Inc. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Merieux Canada Holdings ULC (Canada) | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi (Hangzhou) Pharmaceuticals Co., Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi (China) Investment Co., Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi (Beijing) Pharmaceuticals Co.Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Biologies Co., Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Shenzhen Sanofi pasteur Biological Products Co, Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Shanghai Rongheng Pharmaceutical Co, Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis de Colombia SA | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Korea Co. Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella healthcare Korea Inc. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Gulf FZE | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Egypt | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.80%
Sanofi Hong-Kong Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi India Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 60.40%
Sanofi Healthcare India Private Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 99.90%
Sanofi-Aventis Israël Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi K.K. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
SSP Co.,Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis (Malaysia) SDN. BHD. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Maroc | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis de Mexico SA de CV | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur SA de CV | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Azteca Vacunas, SA de CV | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis de Panama SA | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Panama SA | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Puerto Rico Inc | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Philippines Inc. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Opella Healthcare Philippines Inc. | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Singapore Pte. Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Aventis Pharma (Manufacturing) Pte. Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Manufacturing Pte Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Taiwan Co., Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis (Thailand) Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Pasteur Ltd | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis de Venezuela SA | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi-Aventis Vietnam Company Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 100.00%
Sanofi Vietnam Shareholding Company Limited | Other countries |
Disclosure of subsidiaries [line items] |
Financial interest in principal fully consolidated companies | 85.00%

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_HoechstGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeutschlandGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_A.NattermannCie.GmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBelgiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeFlandersBVBAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareSpainSLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiOyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiWinthropIndustriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRechercheEtDeveloppementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGroupeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChimieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisParticipationsSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurFranceSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaSAFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBiotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMatureIPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurNVLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SECIPESASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurMerieuxSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareInternationalSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareFranceSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareGroupSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymePolyclonalsSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisAEBEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPrivateCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChinoinPrivateCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryCommercialKFTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryKFTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_CarraigInsuranceDACMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeIrelandLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHoldingsIrelandLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareItalySRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeLuxembourgSarlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisNorgeASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiForeignParticipationsB.V.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisSpZooMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePolandSpZOOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurSpZooMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiProdutosFarmaceuticosLdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSROMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareCzechSroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRomaniaSRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareRomaniaSRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUkHoldingsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSynthelaboUKLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaHoldingsLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareUKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AOSanofiRussiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSuisseSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIlacSanayiVeTicaretASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurAsiTicaretASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareTuketiciSalAnonimSirketiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSaglikUrunleriLimitedSirketiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeTherapeuticProductsLimitedPartnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiUSServicesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUSLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisubLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_VaxServeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativUSLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiResearchInvestLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBioverativHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_RPRUSLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_KadmonCorporationLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SynthorxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ProventionBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIBIntermediateHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TargeGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemGBHoldingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TranslateBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSouthAfricaPtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAlgerieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiArabiaTradingCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisArgentinaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHealthcarePtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAustraliaPtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMedleyFarmaceuticaLtdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareBrazilLtdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisCanadaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MerieuxCanadaHoldingsULCCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHangzhouPharmaceuticalsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChinaInvestmentCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBeijingPharmaceuticalsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurBiologiesCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShanghaiRonghengPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeColombiaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisKoreaCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareKoreaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGulfFZEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiEgyptSAEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHongKongLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIndiaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHealthcareIndiaPrivateLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisIsraelLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiKKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SspCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMalaysiaSDNBHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMarocMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeMexicoSADeCVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurS.A.deC.V.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AztecaVacunasSADeCVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDePanamaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePanamaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPuertoRicoIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPhilippinesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePhilippinesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSingaporePteLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaManufacturingPTELTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiManufacturingPteLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiTaiwanCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisThailandLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurThailandLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeVenezuelaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisVietnamCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiVietnamShareholdingCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |